207 related articles for article (PubMed ID: 12125971)
1. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade.
Kayaselçuk F; Zorludemir S; Gümürdühü D; Zeren H; Erman T
J Neurooncol; 2002 Apr; 57(2):115-21. PubMed ID: 12125971
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.
Karamitopoulou E; Perentes E; Diamantis I; Maraziotis T
Acta Neuropathol; 1994; 87(1):47-54. PubMed ID: 7511316
[TBL] [Abstract][Full Text] [Related]
3. Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours.
Kordek R; Biernat W; Alwasiak J; Liberski PP
Acta Neurochir (Wien); 1996; 138(5):509-12; discussion 513. PubMed ID: 8800324
[TBL] [Abstract][Full Text] [Related]
4. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67.
Deckert M; Reifenberger G; Wechsler W
J Cancer Res Clin Oncol; 1989; 115(2):179-88. PubMed ID: 2715168
[TBL] [Abstract][Full Text] [Related]
5. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry.
Møller ML; Braendstrup O
J Neurooncol; 1997 Sep; 34(3):241-6. PubMed ID: 9258816
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
7. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
[TBL] [Abstract][Full Text] [Related]
8. The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome.
Kayaselçuk F; Zorludemir S; Bal N; Erdogan B; Erdogan S; Erman T
J Neurooncol; 2004; 67(1-2):209-14. PubMed ID: 15072469
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors.
Bodey B; Bodey B; Gröger AM; Siegel SE; Kaiser HE
Anticancer Res; 1997; 17(1A):189-96. PubMed ID: 9066650
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of p53-protein expression and the PCNA and Ki-67 proliferating cell indices in human astrocytomas.
Kordek R; Biernat W; Debiec-Rychter M; Alwasiak J; Liberski PP
Pathol Res Pract; 1996 Mar; 192(3):205-9. PubMed ID: 8739466
[TBL] [Abstract][Full Text] [Related]
11. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.
Takeuchi H; Kubota T; Kabuto M; Kitai R; Nozaki J; Yamashita J
Surg Neurol; 1997 Nov; 48(5):501-6. PubMed ID: 9352816
[TBL] [Abstract][Full Text] [Related]
12. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.
Schröder R; Bien K; Kott R; Meyers I; Vössing R
Acta Neuropathol; 1991; 82(5):389-94. PubMed ID: 1767633
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors].
Berny W; Weiser A; Markowska-Woyciechowska A; Jarmundowicz W; Zub W; Załuski R
Neurol Neurochir Pol; 2004; 38(6):457-63. PubMed ID: 15654669
[TBL] [Abstract][Full Text] [Related]
14. Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression.
Khoshyomn S; Lew S; DeMattia J; Singer EB; Penar PL
J Neurooncol; 1999; 45(2):111-6. PubMed ID: 10778726
[TBL] [Abstract][Full Text] [Related]
15. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.
Louis DN; Edgerton S; Thor AD; Hedley-Whyte ET
Acta Neuropathol; 1991; 81(6):675-9. PubMed ID: 1679278
[TBL] [Abstract][Full Text] [Related]
16. Correlation of thallium-201 uptake with proliferating cell nuclear antigen in brain tumours.
Gungor F; Bezircioglu H; Guvenç G; Tezcan M; Yildiz A; Uluc E; Isisag A
Nucl Med Commun; 2000 Sep; 21(9):803-10. PubMed ID: 11065152
[TBL] [Abstract][Full Text] [Related]
17. [Use of tumor proliferation marker ki-67 and PCNA in surgical pathology].
Su J; Zheng J
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):568-71. PubMed ID: 20021977
[No Abstract] [Full Text] [Related]
18. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
Cobb MA; Husain M; Andersen BJ; al-Mefty O
J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
[TBL] [Abstract][Full Text] [Related]
19. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
[TBL] [Abstract][Full Text] [Related]
20. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms.
Prayson RA
Adv Anat Pathol; 2005 May; 12(3):144-8. PubMed ID: 15900115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
